Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opening Product Labeling To Broader CE Data Is Proposed In Senate Bill

Executive Summary

Drug product labels could contain an array of comparative effectiveness data beyond well-controlled clinical trials, if Sens. Jack Reed, D-R.I., and Barbara Mikulski, D-Md., get their way

Related Content

FDA May Allow "Qualitative" Labels For Data In DTC Ads
FDA's DTC Survey Tweaked At PhRMA's Suggestion
DTC Ads To Be Studied By FDA With Eye On Efficacy Presentations
Antipsychotic Labels Will Highlight Need For Proper Diagnoses Of Bipolar Kids
Baucus Takes “Patient-Centered” Focus For Comparative Effectiveness In Bill
House Comparative Effectiveness Bill Includes “Physician Out” Clause
House Comparative Effectiveness Bill Includes “Physician Out” Clause
Commissioner Nominee Hamburg Questioned On FDA’s Role In Health Reform
FDA Poised To Overhaul Distribution Of Consumer Medical Information
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts